Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

N4 Pharma shares rise on partnership with Nanomerics

Tue, 11th Feb 2020 14:19

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has signed a 14-month research collaboration with Nanomerics to produce and test two candidate formulations using its 'Nuvec' delivery system, it announced on Tuesday.
The AIM-traded firm described Nanomerics as a speciality pharmaceutical company focussed on the development of products with enhanced bioavailability.

It said its founders, Ijeoma Uchegbu and Andreas Sch?tzlein, each held chairs at the UCL School of Pharmacy, and described them as "world leaders" in polymeric nanotechnology, having published several books and multiple peer reviewed papers in the field.

As well as being granted more than 20 patents in the field of polymeric nanotechnology, Nanomerics also won first prize for its core molecular envelope technology at the Royal Society of Chemistry's Emerging Technologies Competition 2017, in the health category.

The collaboration would be split into two consecutive phases, each expected to last around seven months.

N4 explained that the first phase would be to develop and test the 30-day stability of four different Nuvec formulations, using both a well characterised plasmid DNA which would allow a broad comparison with existing literature, and a novel small interfering RNA (siRNA).

The second phase would involve testing the efficacy of the plasmid DNA in an in vivo antibody generation model, and include the option to test the siRNA antigen in a gene-silencing tumour model.

N4 said it had secured access to test the novel siRNA antigen by signing a material transfer agreement with an unnamed North American academic institute.

That SiRNA inhibited the production of a protein variant implicated in both cancer and neurodegenerative pathologies, the board said.

"This is an exciting opportunity for the company to accelerate the development of its Nuvec? delivery system," said chief executive officer Nigel Theobald.

"Through our collaboration with Nanomerics we will be gaining access to scientists and laboratories with considerable expertise in the field of nanotechnology delivery system development and testing.

"Demonstrating 30-day stability will be a major milestone in highlighting the potential for Nuvec to be used in a product and, by securing access to a novel siRNA, the company will considerably broaden its data pack showing the versatility and utility of the Nuvec system."

Theobald explained that the first phase of the work would run alongside the existing planned in vitro and in vivo testing of more disperse Nuvec formulations, further details of which the company announced in its interim results on 18 September.

"Phase two will replace the previously planned efficacy work announced in the interim results.

"By working with Nanomerics, the company will now be able to undertake two efficacy studies."

Ijeoma Uchegbu, chief technology officer of Nanomerics, added that the firm was "delighted" to be working with N4 Pharma and its Nuvec delivery system.

"Having reviewed their existing data we can see the potential of the technology and, together with the company, have devised a work programme to advance Nuvec to the next level, with the aim of truly understanding its capabilities and unlocking its potential."

At 1320 GMT, shares in N4 Pharma were up 9% at 3.27p.
More News
15 Jul 2022 13:23

N4 Pharma upbeat on latest tumour suppression study data

(Sharecast News) - Specialist pharmaceutical developer N4 Pharma updated the market on its recent preclinical study with TNF alpha on Friday.

Read more
15 Jul 2022 11:21

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
17 Mar 2022 16:28

UK shareholder meetings calendar - next 7 days

Friday 18 March  
Caracal Gold PLCAGM
Chenavari Toro Income Fund LtdAGM
Monday 21 March 
Aferian PLCAGM
Altona Rare Earths PLCAGM
Helical PLCGM re becoming REIT & buyback
Inland Homes PLCAGM
Tuesday 22 March 
Crest Nicholson Holdings PLCAGM
Hochschild Mining PLCEGM re Amarillo Gold acquisition
Hydro Hotel Eastbourne PLCAGM
Starvest PLCAGM
Sureserve Group plcAGM
Wynnstay Group PLCAGM
Wednesday 23 March 
CML Microsystems PLCGM re employee share plans
Quartix Technologies PLCAGM
Strategic Equity Capital PLCGM re: tender offer
Thursday 24 March 
BlackRock Throgmorton Trust PLCAGM
Independent Investment Trust PLCAGM
N4 Pharma PLCAGM
React Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
23 Feb 2022 14:54

IN BRIEF: N4 Pharma falls as loss widens and Nuvec tests inconclusive

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Reports a pretax loss of GBP1.8 million for 2021, widening 18% from GBP1.6 million the previous year. Says year focused on in vivo studies of Nuvec, a delivery system for cancer treatments and vaccines, which did not return any "meaningful" immunological response in studies carried out by Hamburg-based drug development company Evotec SE. Says that on the back of increased data the company can now narrow its focus on the oncology and gene therapy market.

Read more
31 Jan 2022 22:06

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

TRADING UPDATES: Hiro plans acquisition vehicle IPO; Aquila reviews

Read more
25 Jan 2022 19:12

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

TRADING UPDATES: Cordiant raises GBP200 million; Home REIT spends

Read more
25 Jan 2022 14:50

N4 Pharma outlines work plan after 'encouraging' data

(Sharecast News) - Specialist treatment and vaccine delivery system developer N4 Pharma updated the market on its work plan on Tuesday, following "encouraging data" from its oncology research as announced on 13 December.

Read more
13 Dec 2021 21:57

IN BRIEF: N4 Pharma to focus resources on gene therapy

IN BRIEF: N4 Pharma to focus resources on gene therapy

Read more
13 Dec 2021 14:56

N4 upbeat on cancer treatment progress, vaccine disappoints

(Sharecast News) - Cancer treatment and vaccine delivery system developer N4 Pharma updated the market on data from its proof-of-concept programmes and ongoing activities on Monday.

Read more
1 Nov 2021 06:57

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

IN BRIEF: Kings Arms Yard VCT appoints two new non-executive directors

Read more
1 Oct 2021 09:35

N4 Pharma granted Europe patent with China equivalent on its way

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its 'Nuvec' cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.

Read more
1 Oct 2021 08:50

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

N4 Pharma secures patent in Europe for Nuvec, expects China to follow

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
14 Sep 2021 14:31

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

TRADING UPDATES: Boku launches in Germany; Focusrite trading well

Read more
24 Aug 2021 12:35

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.